Analgesic Ketamine for Battlefield Use

The Defense Health Agency is conducting market research to determine the feasibility of collaborating with industry to develop, manufacture, and receive FDA approval for an analgesic ketamine product for procurement. The product should have certain characteristics, such as being usable in austere, pre-hospital conditions, not requiring reconstitution, and having a shelf life of 2-3 years. The agency is looking for a partner to supply the product, which will be indicated for moderate to severe or severe acute pain upon FDA approval. • The product should be operable in various temperatures and meet statutory and regulatory requirements for manufacturing, storing, and distributing controlled drug substances. • The agency plans to release a request for proposals for the analgesic ketamine product in Fiscal Year 2026. • Respondents should provide a capabilities statement, including information about the product's characteristics, manufacturing lead time, and ability to meet demand surges. • The agency reserves the right to use any non-proprietary technical information in any resultant solicitation.